Rimegepant 75 mg Demonstrates Superiority to Placebo on Nausea Freedom: Results from a Post Hoc Pooled Analysis of 3 Phase 3 Trials in the Acute Treatment of Migraine (2402)
McAllister P, Berman G, Kudrow D, Smith T, Lipton R, Stock E, Stock D, Conway C, Jensen C, Morris B, Coric V, Croop R. Rimegepant 75 mg Demonstrates Superiority to Placebo on Nausea Freedom: Results from a Post Hoc Pooled Analysis of 3 Phase 3 Trials in the Acute Treatment of Migraine (2402). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.2402.Peer-Reviewed Original Research